Wall Street · Urbans Post
By Ed Silverman Sept. 23, 2026 Pharmalot Columnist, Senior Writer Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a couple of more days until the weekend arrives. So keep plugging away.
After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a needed cup of stimulation. Our choice today is hot buttered rum.
A shot of salvation, if you will. Meanwhile, here is the latest menu of tidbits to help you on your way. We hope you conquer the world and have a wonderful day.
And as always, please do stay in touch. We appreciate feedback, tips,and criticism. ... As of next month, a loophole that allows Americans to personally import their medications is closing , The Wall Street Journal tells us.
On Oct. 22, a rule goes into effect requiring medications mailed from abroad to go through a customs process requiring a licensed customs broker and a financial guarantee — a bar few individual mail-order prescriptions have ever had to clear. The U.S. government is trying to crack down on illegal contraband that it says comes into the country through low-value foreign shipments that do not pay tariffs or submit data for tracking. A sizable number of people taking drugs like Ozempic have no medical reason to do so, The New York Times points out, citing a new study.
The analysis of the medical records of more than 92 million U.S. adults identified more than 1.1 million who were taking GLP-1 medications without any record of an issue that would make them eligible, like obesity or diabetes. While the researchers did not examine why people took these medications, doctors said many people are probably using them simply to shed some pounds or in the hope they might deliver other benefits. STAT+ Exclusive Story Already have an account?
Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+.
Subscribe
Source: STAT
